Eupraxia Pharmaceuticals Inc.
EPRX.TO
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -12.65M | -16.71M | -6.36M | -8.74M | -6.76M |
| Total Depreciation and Amortization | 90.10K | 72.80K | 63.00K | 55.40K | 46.50K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -386.60K | 7.14M | 90.70K | 1.85M | 1.42M |
| Change in Net Operating Assets | 2.80M | -231.60K | 1.70M | -1.48M | -707.40K |
| Cash from Operations | -10.15M | -9.73M | -4.51M | -8.32M | -6.00M |
| Capital Expenditure | -327.00K | -193.30K | -60.40K | -166.20K | -169.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -79.72M | -- | -- | -- | -- |
| Cash from Investing | -80.05M | -193.30K | -60.40K | -166.20K | -169.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 68.58M | 1.49M | 73.90M | 239.80K | 429.90K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 68.58M | 1.49M | 73.90M | 239.80K | 429.90K |
| Foreign Exchange rate Adjustments | -448.20K | 33.90K | -137.30K | 552.70K | 95.50K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -22.06M | -8.40M | 69.19M | -7.69M | -5.65M |